Filtered By:
Source: Diabetes and Metabolism
This page shows you your search results in order of date. This is page number 3.
Order by Relevance | Date
Total 66 results found since Jan 2013.
Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study
Diabetes Metab. 2023 Jan 3:101418. doi: 10.1016/j.diabet.2022.101418. Online ahead of print.ABSTRACTBACKGROUND: Continued expansion of indications for sodium-glucose cotransporter-2 inhibitors increases importance of evaluating cardiovascular and kidney efficacy and safety of empagliflozin in patients with type 2 diabetes compared to similar therapies.METHODS: The EMPRISE Europe and Asia study is a non-interventional cohort study using data from 2014-2019 in seven European (Denmark, Finland, Germany, Norway, Spain, Sweden, United Kingdom) and four Asian (Israel, Japan, South Korea, Taiwan) countries. Patients with type 2 d...
Source: Diabetes and Metabolism - January 7, 2023 Category: Endocrinology Authors: Avraham Karasik Stefanie Lanzinger Elise Chia-Hui Tan Daisuke Yabe Dae Jung Kim Wayne H-H Sheu Cheli Melzer-Cohen Reinhard W Holl Kyoung Hwa Ha Kamlesh Khunti Francesco Zaccardi Anuradhaa Subramanian Krishnarajah Nirantharakumar Thomas Nystr öm Leo Niska Source Type: research
Antidiabetic agents and risk of atrial fibrillation/flutter: a comparative critical analysis with a focus on differences between SGLT2 inhibitors and GLP-1 receptor agonists
Diabetes Metab. 2022 Sep 25:101390. doi: 10.1016/j.diabet.2022.101390. Online ahead of print.ABSTRACTAtrial fibrillation/flutter (AF/AFL) is a common cardiac arrhythmia in patients with diabetes and is associated with an increased risk of morbidity, including ischaemic stroke and heart failure, and mortality. Different classes of glucose-lowering agents have shown distinct effects on the risk of stroke and heart failure. Their effects on cardiac arrhythmias such as AF/AFL have not been carefully investigated yet and even less their possible relationship with classical complications such as stroke and heart failure. The pre...
Source: Diabetes and Metabolism - September 28, 2022 Category: Endocrinology Authors: Andr é J Scheen Source Type: research
Comment on "Elevated triglyceride-glucose index predicts risk of incident ischemic stroke: The Rural Chinese cohort study"
Diabetes Metab. 2021 Dec 18:101314. doi: 10.1016/j.diabet.2021.101314. Online ahead of print.NO ABSTRACTPMID:34933119 | DOI:10.1016/j.diabet.2021.101314
Source: Diabetes and Metabolism - December 21, 2021 Category: Endocrinology Authors: Roomi Raja Satesh Kumar Source Type: research
Heart failure hospitalisation relative to major atherosclerotic events in type 2 diabetes with versus without chronic kidney disease: a meta-analysis of cardiovascular outcomes trials
CONCLUSION: CKD is associated with a shift in the profile of cardiovascular events in people with type 2 diabetes, marked by a disproportionate increase in HHF relative to MACE.PMID:33744399 | DOI:10.1016/j.diabet.2021.101249
Source: Diabetes and Metabolism - March 21, 2021 Category: Endocrinology Authors: Julian W Sacre Dianna J Magliano Jonathan E Shaw Source Type: research
